Twist NEW cfDNA Pan-Cancer Reference Standard v2!
Introducing Twist NEW cfDNA Pan-Cancer Reference Standard v2 to assist researchers in the development of NGS-based assays.
NGS-based liquid biopsy is a rapidly evolving application that requires accurate and precise reference standards. The Twist cfDNA Pan-Cancer Reference Standard v2 is a comprehensive tool created to assist researchers in the development of NGS-based assays and the ongoing monitoring of high-quality, clinically relevant variants.
Ideal for establishing essential analytical parameters, Limit of Detection (LoD) and the Limit of Blank (LoB). Composed of wild-type (WT) background cell-free DNA (cfDNA) from a cell-line and synthetic oligos carrying mutant alleles, this reference material offers the precision and sensitivity needed for researching liquid biopsy assay development.
Key Benefits:
Comprehensive Detection of Cancer Variants
456 unique naturally occurring cancer variants
132 clinically relevant variants
Covers 84 different genes involved in cancer
Exceptional Sensitivity of Background DNA
Background cfDNA derived from non-amplified cell-line DNA
DNA size profile and post-sequencing profile mimic native cfDNA
Designed for Precision and Flexibility
Seven individual variant allele percentages to choose from in large and small configurations
Digital Droplet PCR verification of VAF percentages
Convenient test set of all VAF percentages available
*For research use only. Not for use in any diagnostic or clinical procedures.
Click here to know more!
For more information on Twist’s NEW cfDNA Pan-Cancer Reference Standard v2, feel free to reach out to any of our Sales Representatives at [email protected] or call 6777 1045.